BioWorld

Sep. 19, 2006

View Archived Issues

CTI, Novartis Enter Xyotax Deal; Option On Pixantrone

In a two-part arrangement, Cell Therapeutics Inc. agreed to partner Xyotax (poliglumex paclitaxel) with Novartis AG in a deal worth up to $285 million, and there's an option for another $111.5 million deal for pixantrone. (BioWorld Today) Read More

TransTech RAGE Modulators Subject Of $173M Pfizer Deal

Read More

Glaxo Submits Application For Tykerb In Breast Cancer

Read More

Syntonix Gets Serono Vote Again: Potential $54M Deal

Read More

Sirion Gains $25M Through Takeover By Tenby Pharma

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More

Other News To Note

Read More